Ostarine vs RAD 140 | Which SARM is Better

SARMs are a class of investigational compounds. Scientists are studying them to learn how they interact with androgen receptors in the body. Among the most commonly studied SARMs are Ostarine (MK-2866) and RAD 140 (Testolone).

This blog compares both based on available lab data, focusing on their structure, function, and observations in research models.

What is Ostarine (MK-2866)?

Ostarine, also known as MK-2866, is a non-steroidal research compound. It was developed to help scientists explore how SARMs affect muscle and bone tissues in preclinical models.

Chemical Structure

CAS no: 841205-47-8

Molecular Formula: C₁₉H₁₄F₃N₃O₃

Molecular Weight: 389.3 g/mol

Mechanism of Action

In research, Ostarine binds to androgen receptors in a targeted way. This interaction may promote anabolic activity in muscle and bone cells, with minimal effects on other organs.

Preclinical studies suggest that this selectivity helps reduce unwanted activity in the prostate or liver tissues of research subjects.

What is RAD 140 (Testolone)?

RAD 140, also known as Testolone, is another SARM under study. It is known with a unique tetrahydropyridopyrimidine structure. Like Ostarine, it is designed to bind selectively to androgen receptors. However, its structure may give it a stronger response in certain tissues.

Chemical Structure

CAS no: 1192367-47-0

Molecular Formula: C₂₀H₁₆CIN₅O₂

Molecular Weight: 398.8 g/mol

Mechanism of Action

In lab models, RAD 140 shows strong binding to androgen receptors. This may lead to increased protein synthesis and cellular growth. Unlike anabolic steroids, it does not convert into estrogen. Early research also explores its potential effect on neuroprotection and fat metabolism.

Ostarine vs RAD 140: Side-by-Side Comparison Table

Feature	Ostarine	RAD 140
Classification	SARM	SARM
Half Life	~24 hours	~16-20 hours
Binding Strength	Moderate	Strong
Anabolic Activity (in lab models)	Mild to moderate	Strong
Estrogen Conversion	None	None
Investigational Use	Muscle wasting, bone health	Muscle growth, neuroprotection

Key Differences between Ostarine and RAD 140 in Research

• Anabolic Strength: RAD 140 shows stronger anabolic signals in test models compared to Ostarine.
• Side Effect Profile: Ostarine may cause fewer hormonal changes, while RAD 140 might lead to more hormonal suppression in lab animals.
• Application Focus: Ostarine is often studied for muscle wasting and bone loss, while RAD 140 is studied for performance enhancement and hormonal-sensitive conditions.
• Potency: RAD 140 may strongly bind to receptors, which may result in stronger biological effects.

Potential Benefits Observed in Preclinical Models

Ostarine (MK-2866)

• May support lean muscle growth in animal studies
• Shows promise in improving bone strength in lab models
• Possibly helps in recovery after injury in lab settings

RAD 140 (Testolone)

• Strong anabolic signals may promote greater muscle gain in animal models
• Appears to reduce fat mass in some rodent models
• It may have protective effects on brain cells in early studies.

Possible Side Effects Noted in Animal or Cell Studies

Ostarine

• May cause mild hormonal suppression in experimental models
• Some liver enzyme changes were observed in high doses

RAD 140

• Hormonal suppression is more noticeable in test subjects
• Slight liver stress markets noted in long-term trials in lab models
• Aggressive behavior is seen in some rodent models

Where to buy Ostarine and RAD 140 online for research purposes?

PureRawz is a trusted supplier you can buy RAD 140 & Ostarine for laboratory research purposes only.

Each product includes a reference-grade Certificate of Analysis (COA). This verifies purity, identity, and concentration.

Legal Status and Research Guidelines

Ostarine and RAD 140 are not approved for human or veterinary use. They are classified as investigational chemicals. Most countries allow their use only for scientific research. They are listed on the World Anti-Doping Agency (WADA) banned substance list for athletes.

Researchers must follow proper storage, labeling, and ethical guidelines while using these substances in labs.

FAQs

Can Ostarine and RAD 140 be used together in research studies?

Yes, some studies explore their combined effects. However, stacking may increase the risk of hormonal suppression in lab animals.

Which SARM has stronger anabolic effects based on lab data?

RAD 140 generally shows stronger anabolic activity than Ostarine in preclinical studies.

Are there known interactions with other investigational compounds?

Some studies examine combinations with PPAR agonists, growth factors, or peptides. Effects may vary based on dosing and duration.

Is RAD 140 more suppressive than Ostarine in test models?

Yes, RAD 140 tends to cause stronger suppression of natural hormone levels in animal models.

How should researchers store these SARMs for stability?

Store in a cool, dry place away from light. Most labs keep them at room temperature or in cold storage based on the form (liquid or powder).

Conclusion

Ostarine and RAD 140 are among the most widely studied SARMs in the lab setting. Ostarine may offer a safer profile with milder effects, while RAD 140 shows stronger anabolic potential.

The best choice depends on the research goal, such as studying muscle growth, bone health, or neuroprotection. Both should be handled carefully and used only under approved laboratory guidelines.

Disclaimer

This content is for learning only and not medical advice. These products are for research use only. Research should follow IRB or IACUC rules. Please double-check all information before buying. By ordering, you agree to our Terms and Conditions. If you are not 100% satisfied with the product you received, please contact us at support@purerawz.co

ATTENTION: All our products are for LABORATORY AND RESEARCH PURPOSES ONLY. They are not for veterinary or human usage.

References

1. Dalton, J. T., Taylor, R. P., Mohler, M. L., & Steiner, M. S. (2013). Selective androgen receptor modulators for male and female osteoporosis: prospects for a novel therapeutic approach. Bone, 52(1), 36–43. Narayanan, R., Mohler, M. L., & Dalton, J. T. (2018). The Therapeutic Potential of Selective Androgen Receptor Modulators. Endocrine Reviews, 39(3), 313–320. 
2. Solimini, R., Rotolo, M. C., Mastrobattista, L., & Pichini, S. (2024). The evolving risk profile of SARMs misuse. Toxics, 12(2), 77. 
3. U.S. Food and Drug Administration. (2022). FDA warns against the use of Selective Androgen Receptor Modulators (SARMs) among teens and young adults.